Personalised management of Chronic Obstructive Pulmonary Disease (COPD): Malaysian consensus algorithm for appropriate use of inhaled corticosteroid (ICS) in COPD patients
- Author:
Nurhayati Mohd Marzuki
1
;
Mat Zuki Mat Jaeb
;
Andrea Ban
;
Ahmad Izuanuddin Ismail
;
Irfhan Ali Hyder Ali
;
Mohd Razali Norhaya
;
Azlina Samsudin
;
Mona Zaria Nasaruddin
;
Rozanah Abd Rahman
;
Mohd Arif Mohd Zim
;
Razul Md. Nazri B Md Kassim
;
Yoke Fong Lam
;
Aishah Ibrahim
;
Noor Aliza Mohd Tarekh
;
Sandip Vasantrao Kapse
Author Information
- Publication Type:Review
- Keywords: COPD; ICS; Malaysian consensus statemen; Dual bronchodilator
- From: The Medical Journal of Malaysia 2020;75(6):717-721
- CountryMalaysia
- Language:English
- Abstract: Background: Regarding the long-term safety issues with the use of inhaled corticosteroids (ICS) and the clinical predominance of dual bronchodilators in enhancing treatment outcomes in chronic obstructive pulmonary disease (COPD), ICS is no longer a “preferred therapy” according to the Global Initiative for Chronic Obstructive Lung Disease except on top of a dual bronchodilator. This has necessitated a change in the current therapy for many COPD patients. Objective: To determine a standardised algorithm to reassess and personalise the treatment COPD patients based on the available evidence. Methods: A consensus statement was agreed upon by a panel of pulmonologists in from 11 institutes in Malaysia whose members formed this consensus group. Results: According to the consensus, which was unanimously adopted, all COPD patients who are currently receiving an ICS-based treatment should be reassessed based on the presence of co-existence of asthma or high eosinophil counts and frequency of moderate or severe exacerbations in the previous 12 months. When that the patients meet any of the aforementioned criteria, then the patient can continue taking ICS-based therapy. However, if the patients do not meet the criteria, then the treatment of patients need to be personalised based on whether the patient is currently receiving long-acting beta-agonists (LABA)/ICS or triple therapy. Conclusion: A flowchart of the consensus providing a guidance to Malaysian clinicians was elucidated based on evidences and international guidelines that identifies the right patients who should receive inhaled corticosteroids and enable to switch non ICS based therapies in patients less likely to benefit from such treatments.
